

STIC-Biotech/ChemLib

106254

From: Wax, Robert
Sent: Monday, October 20, 2003 2:14 PM
To: STIC-Biotech/ChemLib
Subject: Litigation search for 09/994,164

For: **Bob Wax**
Employee #61940
Mail Box 9B01
Art Unit 1653
Rm 11D05, CM1
308-4471

In Application No. **09/ 994,164**

Please perform a litigation search on US Patent 6,262,019 for use in this reissue application.

Thank you very much in advance.

Bob

Robert A. Wax
Primary Examiner
Art Unit 1653
Office: CM1, 11 D 05
Mailbox: CM1, 9 B 01
Voice: (703) 308-4471
Fax: (703) 746-9841

Searcher: _____
Phone: _____
Location: _____
Date Picked Up: _____
Date Completed: _____
Searcher Prep/Review: _____
Clerical: _____
Online time: _____

TYPE OF SEARCH:
NA Sequences: _____
AA Sequences: _____
Structures: _____
Bibliographic: _____
Litigation: _____
Full text: _____
Patent Family: _____
Other: _____

VENDOR/COST (where applic.)
STN: _____
DIALOG: _____
Questel/Orbit: _____
DRLink: _____
Lexis/Nexis: _____
Sequence Sys.: _____
WWW/Internet: _____
Other (specify): _____

s e3

S2 1 PN='US 6262019'
 ?t 1/39/1

1/39/1
 >>>Item 1 is not within valid item range
 ?t 2/39/1

2/39/1
 DIALOG(R)File 345:Inpadoc/Fam.& Legal Stat
 (c) 2003 EPO. All rts. reserv.

15498267
 Basic Patent (No,Kind,Date): WO 9955326 A1 19991104 <No. of Patents: 002>
 Patent Family:

Patent No	Kind	Date	Applic No	Kind	Date
US 6262019	BA	20010717	US 302217	A	19990429
WO 9955326	A1	19991104	WO 99US9485	A	19990429 (BASIC)

Priority Data (No,Kind,Date):
 US 302217 A 19990429
 US 83661 P 19980430

PATENT FAMILY:

UNITED STATES OF AMERICA (US)

Patent (No,Kind,Date): US 6262019 BA 20010717
 METHOD OF TREATMENT OF GLUTATHIONE DEFICIENT MAMMALS (English)
 Patent Assignee: VIT IMMUNE L C (US)
 Author (Inventor): KELLER ROBERT H (US); KIRCHENBAUM DAVID W (US)
 Priority (No,Kind,Date): US 302217 A 19990429; US 83661 P 19980430
 Applic (No,Kind,Date): US 302217 A 19990429
 National Class: * 514002000; 514002000; 514007000; 514012000;
 514023000; 514021000; 514251000; 514276000; 424054000; 424049000;
 424535000; 424655000; 530365000; 530833000
 IPC: * A01N-037/18; A61K-038/02
 CA Abstract No: * 131(24)317792M
 Derwent WPI Acc No: * C 00-023254
 Language of Document: English

UNITED STATES OF AMERICA (US)

Legal Status (No,Type,Date,Code,Text):

US 6262019	P	19980430	US AA	PRIORITY (US PROVISIONAL APPLICATION)
			US 83661 P	19980430
US 6262019	P	19990429	US AE	APPLICATION DATA (PATENT) (APPL. DATA (PATENT))
			US 302217 A	19990429
US 6262019	P	20010717	US BA	PATENT (NO PREVIOUS PRE-GRANT PUBLICATION)
US 6262019	P	20020101	US CC	CERTIFICATE OF CORRECTION
US 6262019	P	20020226	US RF	REISSUE APPLICATION FILED (REISSUE APPL. FILED)
				20011126

WORLD INTELLECTUAL PROPERTY ORGANIZATION, PCT (WO)

Patent (No,Kind,Date): WO 9955326 A1 19991104
 METHOD OF TREATMENT OF GLUTATHIONE DEFICIENT MAMMALS (English)
 Patent Assignee: VIT IMMUNE L C (US)
 Author (Inventor): KELLER M D ROBERT H; KIRCHENBAUM DAVID W
 Priority (No,Kind,Date): US 83661 P 19980430
 Applic (No,Kind,Date): WO 99US9485 A 19990429
 Designated States: (National) CA; JP (Regional) AT; BE; CH; CY; DE;

DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE
 Filing Details: WO 130000 With international search report; Before
 expiration of time limit for amending the claims and to be
 republished in the event of the receipt of the amendments
 IPC: * A61K-031/195; A61K-031/34
 CA Abstract No: * 131(24)317792M; 131(24)317792M
 Derwent WPI Acc No: * C 00-023254; C 00-023254
 Language of Document: English

WORLD INTELLECTUAL PROPERTY ORGANIZATION, PCT (WO)

Legal Status (No, Type, Date, Code, Text):

WO 9955326	P	19980430	WO AA	PRIORITY CLAIMED
			US 83661	P 19980430
WO 9955326	P	19990429	WO AE	APPLICATION DATA (APPL. DATA)
			WO 99US9485	A 19990429
WO 9955326	P	19991104	WO AK	DESIGNATED STATES CITED IN A PUBLISHED APPLICATION WITH SEARCH REPORT (DESIGNATED STATES CITED IN A PUBLISHED APPL. WITH SEARCH REPORT)
			CA JP	
WO 9955326	P	19991104	WO AL	DESIGNATED COUNTRIES FOR REGIONAL PATENTS CITED IN A PUBLISHED APPLICATION WITH SEARCH REPORT (DESIGNATED COUNTRIES FOR REGIONAL PATENTS CITED IN A PUBLISHED APPL. WITH SEARCH REPORT)
			AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE	
WO 9955326	P	19991104	WO A1	PUBLICATION OF THE INTERNATIONAL APPLICATION WITH THE INTERNATIONAL SEARCH REPORT (PUB. OF THE INTERNATIONAL APPL. WITH THE INTERNATIONAL SEARCH REPORT)
WO 9955326	P	19991229	WO 121	EP: PCT APP. ART. 158 (1) (EP: PCT ANM. ART. 158 (1))
WO 9955326	P	20000302	WO DFPE	REQUEST FOR PRELIMINARY EXAMINATION FILED PRIOR TO EXPIRATION OF 19TH MONTH FROM PRIORITY DATE
WO 9955326	P	20010829	WO 122	EP: PCT APP. NOT ENT. EUROP. PHASE (EP: PCT ANM. NICHT IN EUROP. PHASE EING.)

?

WAX 09/994,164
Current session 18/11/2003

Query/Command : ..ba pluspat; (us6262019)/PN /XPN

Selected file: PLUSPAT

PLUSPAT - (c) Questel-Orbit, All Rights Reserved.
Comprehensive Worldwide Patents database
New Patent Citation Commands & FAM Citation Report - see INFO PATCITE
Last update of file: 2003/11/14 (YYYY/MM/DD) 2003-45/UP (basic update)

**** SS 1: Results 1**

Search statement 2

Query/Command : PRT SS 1 MAX 1 LEGALALL

1 / 1 PLUSPAT - @QUESTEL-ORBIT

Patent Number :

US6262019 B1 20010717 [US6262019]

Title :

(B1) Method of treatment of glutathione deficient mammals

Patent Assignee :

(B1) VIT IMMUNE L C (US)

Patent Assignee :

Vit-Immune, L. C., Hollywood FL [US]

Inventor(s) :

(B1) KIRCHENBAUM DAVID W (US); KELLER ROBERT H (US)

Application Nbr :

US30221799 19990429 [1999US-0302217]

Filing Details :

Rel. Prov. 60/083,661 19980430 [1998US-P083661]

Priority Details :

US30221799 19990429 [1999US-0302217]

US8366198P 19980430 [1998US-P083661]

Intl Patent Class :

(B1) A01N-037/18 A61K-038/02

EPO ECLA Class :

A23L-001/30C2

A23L-001/302

A23L-001/305A

US Patent Class :

ORIGINAL (O) : 514002000; CROSS-REFERENCE (X) : 424049000 424054000

424535000 424655000 514007000 514012000 514021000 514023000

514251000 514276000 530365000 530833000

Document Type :

Basic

Citations :

US4256760; US4277496; US4292403; US5290571; US5456924; US5696109

PROMT on STN, Information Access Company, 1998: 1310, BioDynamax

Supplement--Ultra Antioxidants Tablets, Product Alert (Dec. 22, 1997)

ISSN: 0740-3801.*

"Screening of Potential Chemopreventive Agents Using Biochemical Markets

of Carcinogenesis" by Sheela Sharma, Jill D. Stutzman, Gary J. Kelloff and Vernon E. Steele, Cancer Resreach 54, 5848-5855, Nov. 15, 1994.

Low Blood Glutathione Levels in Healthy Aging Adults, pp 720-725, Calvin A. Long, et al.

a-Lipoic Acid: Biological Effects and Clinical Implications, pp 177-183, Trent W. Nichols, Jr. M.D.

Glutathione: Systemic Protectant Against Oxidative and Free Radical Damage, pp 155-171, 173-176, Parris M. Kidd, Ph.D.

Importance And Regulation of Hepatic Glutathione, pp 251-266, Laurie D. Deleve, M.D., Ph.D. et al.

Probiotics in Human Medicine, pp 439-442, R. Fuller.

Aids Wasting Syndrome as an Entero--Metabolic Disorder: The Gut Hypothesis, pp 40-45, 47-43, Mitchell Kaminski, Jr., M.D., et al.

The Effects of L-Glutamine, N-Acetyl-D-Glucosamine, Gamma-Linolenic Acid and Gamma-Oryzanol on Intestinal Permeability.

Publication Stage :

(B1) U.S. Patent (no pre-grant pub.) after Jan. 2, 2001

Abstract :

Glutathione (GSH) is a tripeptide of extreme importance as a catalyst, reductant, and reactant. It can be depleted intracellularly either by forming a direct complex with an electrophilic agent (accomplished investigationaly by agents such as bromobenzene or diethyl maleate), by way of inhibition of synthesis, or by subjecting cells to oxidant stress. Most cells, except for epithelia cells, do not have a direct transport capacity for intact GSH. Non-epithelial cells must either transport precursor substrates for GSH synthesis or salvage amino acids from circulating GSH for reuse in intracellular resynthesis. Dietary cysteine is a rate limiting substrate for the synthesis of glutathione and also inhibits GSH efflux. Although GSH is synthesized from precursors in virtually all cells, the liver is the main source of plasma GSH. Protection and support of liver function is paramount to elevating GSH levels. The disclosure is also of a unique combination of nutritional supplements including n-acetyl cysteine, vitamin C, l-glucosamine, n-acetyl d-glucosamine, quercitin, sylimarin, Alpha lipoic acid and high protein, low fat whey that are combined to support various bodily systems involved in glutathione synthesis, reutilization and storage; all intended to elevate glutathione concentration in the mammalian cell.

Update Code :

2001-29

1 / 1 LGST - ©EPO

Patent Number :

US6262019 B1 20010717 [US6262019]

Application Number :

US30221799 19990429 [1999US-0302217]

Action Taken :

20020101 US/CC-A

CERTIFICATE OF CORRECTION

20020226 US/RF-A

REISSUE APPLICATION FILED

EFFECTIVE DATE: 20011126

Update Code :

2003-22

1 / 1 CRXX - ©CLAIMS/RRX

Patent Number :

6,262,019 A 20010717 [US6262019]

Patent Assignee :

Vit-Immune L C

Actions :

20011126 REISSUE REQUESTED

ISSUE DATE OF O.G.: 20020226

REISSUE REQUEST NUMBER: 09/994164

EXAMINATION GROUP RESPONSIBLE FOR REISSUEPROCESS: 1653

Reissue Patent Number:

20020101 CERTIFICATE OF CORRECTION

Query/Command : st